Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LERCANIDIPINE Cause Electrocardiogram qt prolonged? 47 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 47 reports of Electrocardiogram qt prolonged have been filed in association with LERCANIDIPINE. This represents 1.3% of all adverse event reports for LERCANIDIPINE.

47
Reports of Electrocardiogram qt prolonged with LERCANIDIPINE
1.3%
of all LERCANIDIPINE reports
1
Deaths
20
Hospitalizations

How Dangerous Is Electrocardiogram qt prolonged From LERCANIDIPINE?

Of the 47 reports, 1 (2.1%) resulted in death, 20 (42.6%) required hospitalization, and 34 (72.3%) were considered life-threatening.

Is Electrocardiogram qt prolonged Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LERCANIDIPINE. However, 47 reports have been filed with the FAERS database.

What Other Side Effects Does LERCANIDIPINE Cause?

Acute kidney injury (424) Hypotension (401) Fall (323) Hypertension (197) Hyperkalaemia (176) Drug ineffective (149) Diarrhoea (122) Hyponatraemia (122) Renal impairment (120) Oedema peripheral (114)

What Other Drugs Cause Electrocardiogram qt prolonged?

QUETIAPINE (1,869) OLANZAPINE (1,325) RIBOCICLIB (1,020) AMIODARONE (1,000) HYDROXYCHLOROQUINE (992) CLOZAPINE (958) CITALOPRAM HYDROBROMIDE (917) ESCITALOPRAM OXALATE (899) ONDANSETRON (881) BUPROPION (853)

Which LERCANIDIPINE Alternatives Have Lower Electrocardiogram qt prolonged Risk?

LERCANIDIPINE vs LETAIRIS LERCANIDIPINE vs LETERMOVIR LERCANIDIPINE vs LETROZOLE LERCANIDIPINE vs LETROZOLE\RIBOCICLIB LERCANIDIPINE vs LEUCOVORIN

Related Pages

LERCANIDIPINE Full Profile All Electrocardiogram qt prolonged Reports All Drugs Causing Electrocardiogram qt prolonged LERCANIDIPINE Demographics